about
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effectsDelta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THCThe cannabinoid acids, analogs and endogenous counterpartsEndocannabinoids control platelet activation and limit aggregate formation under flowThe grass isn't always greener: The effects of cannabis on embryological developmentMedical cannabis - the Canadian perspectiveCurrent Therapeutic Cannabis Controversies and Clinical Trial Design IssuesExogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic reviewBehavioral Characterization of the Effects of Cannabis Smoke and Anandamide in RatsIntracerebroventricular injections of dronabinol, a cannabinoid receptor agonist, does not attenuate serotonin-induced apnea in Sprague-Dawley ratsStructure elucidation of the designer drug N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-3-(4-fluorophenyl)-pyrazole-5-carboxamide and the relevance of predicted (13) C NMR shifts - a case study.An Atmospheric Pressure Ionization MS/MS Assay using Online Extraction for the Analysis of 11 Cannabinoids and Metabolites in Human Plasma and Urine.Fatty Acid Binding Protein-1 (FABP1) and the Human FABP1 T94A Variant: Roles in the Endocannabinoid System and Dyslipidemias.Medical marijuana and driving: a review.In vitro metabolism and metabolic effects of ajulemic acid, a synthetic cannabinoid agonist.Fatty acid-binding proteins (FABPs) are intracellular carriers for Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD).FABP1: A Novel Hepatic Endocannabinoid and Cannabinoid Binding Protein.The therapeutic potential of cannabinoids for movement disorders.Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography-tandem mass spectrometry.Medical marijuana in the workplace: challenges and management options for occupational physiciansMonohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity.Influence of alcohol and other substances of abuse at the time of injury among patients in a Norwegian emergency department.Plasma Cannabinoid Pharmacokinetics After Controlled Smoking and Ad libitum Cannabis Smoking in Chronic Frequent Users.Cannabinoid potentiation of glycine receptors contributes to cannabis-induced analgesia.Prevalence and correlates of hashish use in a national sample of high school seniors in the United States.Association Between Use of Cannabis in Adolescence and Weight Change into MidlifeChemistry, metabolism, and toxicology of cannabis: clinical implications.Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?Teen Use of Marijuana Edibles: A Focus Group Study of an Emerging Issue.Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving lawsEstablishing legal limits for driving under the influence of marijuana.Deficits in striatal dopamine release in cannabis dependence.Acute Effects of Marijuana Smoking on Negative and Positive Affect.Controlled release tablet formulation containing natural Δ(9)-tetrahydrocannabinolEndocannabinoids: A Promising Impact for Traumatic Brain Injury.Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation.Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain.Cannabis use: a perspective in relation to the proposed UK drug-driving legislation.The dilemma of medical marijuana use by rheumatology patients.Delta(9) -tetrahydrocannabinol and cannabidiol as potential curative agents for cancer: A critical examination of the preclinical literature.
P2860
Q24606148-2A93A124-18DA-450B-9A0D-457DBE607461Q24634909-CA4972C9-B9FC-46BA-B318-3185C8E250B3Q27009735-1AC0CF03-C8AC-4538-A440-393452BF98FFQ27345221-9A3B9995-B068-4F9E-9A99-AE1C05CEEFA8Q28067383-B65CF541-4201-49FA-93D7-54E3E3D238E8Q28069855-EFC39283-9475-4A1E-9010-8FA9DA4ADF38Q28071794-487ABD69-EB97-471A-BB76-CA07D2131BA0Q28300877-17F53388-D585-4A7D-A984-300DC743E3DAQ28551268-DD4033CB-C315-4B14-B7D0-0DD4D14AC7BBQ28603498-8616380D-CB79-4FA9-9451-7A125B4A8EE2Q30487997-F77E8661-8D33-4503-99A5-436674630558Q33470761-150AE488-01B7-477C-9EC8-8704F30BAC30Q33613330-CE7FE5CD-F1F0-48E8-9A6E-3A0D41A47246Q34079086-3DFE6657-B09B-4D6D-8E51-D349F44E3503Q34292559-71AC632D-E2C9-477A-B766-1C788BCF0A22Q34461976-BD586BB5-DEE5-41BB-BF45-7890A8AEA570Q34538205-749D56FB-ACD6-434F-AD39-8FDEED198B45Q35171113-6A7AB10A-AD07-408E-84EF-311E1B36475BQ35173356-642DE821-AC20-4F3E-9320-C7E48DDC57A3Q35542153-34C86279-28CF-4295-9266-2EED823E6515Q35785005-0786F7D4-AD5F-43F3-8349-D13B517788C4Q36045507-9D4D5CEC-FDB2-4774-9E70-CA47CA3B1AFCQ36062692-2C455CF5-42D2-407D-850B-FB9F24EEF94DQ36072716-341847C9-5330-459D-BD04-6B9F4F1C3490Q36169683-0393B5F1-C780-4E85-BEAC-3384B2A79757Q36242504-DB4EC612-FBC2-4DDC-B35C-1FA1C7E90F3FQ36604757-2DF6B5B3-77B1-4D3A-9BB9-00446F559833Q36729404-6FC77B1B-29FE-4033-9C77-D12D4E9DA9C4Q36892724-DE68B756-E736-49CA-BD58-FA4E804BF1CAQ37029547-FD993E71-B0BE-4F6D-BE13-320B90BF4791Q37218871-16624A7F-6092-4837-B845-5BB16468C09CQ37276855-1CF0F990-42B0-447B-BCE5-32F262DE4E53Q37366043-93C81B6A-4DE3-4B53-BFF1-477ED91EA47CQ37397648-3AFA59C1-2C6B-4975-8C5A-EB31550AF0E7Q37648343-13C70EAC-5DF5-48DB-B164-D38F18728479Q38087533-3D51898C-0498-4214-A65B-D231913E0182Q38102053-E5B6B550-7333-4514-9097-8C8C0E207BB5Q38170324-953DA171-0FD9-4172-A84C-BEF5D0BFD13DQ38193035-EDA34D40-A128-42CE-8040-634AC4327F0CQ38351132-10E02FFB-08C4-4F80-A226-2650CCF0166C
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Human cannabinoid pharmacokinetics
@ast
Human cannabinoid pharmacokinetics
@en
Human cannabinoid pharmacokinetics
@nl
type
label
Human cannabinoid pharmacokinetics
@ast
Human cannabinoid pharmacokinetics
@en
Human cannabinoid pharmacokinetics
@nl
prefLabel
Human cannabinoid pharmacokinetics
@ast
Human cannabinoid pharmacokinetics
@en
Human cannabinoid pharmacokinetics
@nl
P2860
P3181
P356
P1476
Human cannabinoid pharmacokinetics
@en
P2093
Marilyn A Huestis
P2860
P304
P3181
P356
10.1002/CBDV.200790152
P407
P577
2007-08-01T00:00:00Z